Index

A

Abbreviated New Drug Submission (ANDS), 19–20, 52, 56, 120
approvals, 110, 113
NOC Regulations, 62–3, 74
Anatomical Therapeutic Classification (ATC) System, 156, 166–8, 191
appropriation, 224
AstraZeneca v. Canada, 29, 215
automatic stay, 27, 214, 222, 253

B

benefit-risk:
analysis, 22, 79
profile, 19–21, 23, 79, 115, 132, 150
Bill C-22, 202–4, 207, 228
Bill C-51, 48, 49, 70–1, 79, 82, 86, 115
Bill C-91, 202, 217–19, 225–6, 228
debate preceding, 203–8
impact, 206–7
bioequivalent drugs, 27, 126
blockbuster drugs, 25–6, 29, 103, 153, 217, 221, 224, 227, 252
market exclusivity, 228
patent protection, 183, 225
blocking patents, 123–4
brand name drugs, 3, 6, 19, 51, 113, 149, 153, 224
brand-name pharmaceutical firms, 19, 21, 65–7, 73 ...

Get Patently Innovative now with the O’Reilly learning platform.

O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.

Start your free trial